- Home
- EMF vs AMRN Comparison
EMF vs AMRN Comparison
Compare EMF & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMF
- AMRN
- Stock Information
- Founded
- EMF 1987
- AMRN 1989
- Country
- EMF United States
- AMRN Ireland
- Employees
- EMF N/A
- AMRN N/A
- Industry
- EMF Finance/Investors Services
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- EMF Finance
- AMRN Health Care
- Exchange
- EMF Nasdaq
- AMRN Nasdaq
- Market Cap
- EMF 219.3M
- AMRN 317.1M
- IPO Year
- EMF N/A
- AMRN 1993
- Fundamental
- Price
- EMF $16.51
- AMRN $14.93
- Analyst Decision
- EMF
- AMRN Strong Sell
- Analyst Count
- EMF 0
- AMRN 1
- Target Price
- EMF N/A
- AMRN $12.00
- AVG Volume (30 Days)
- EMF 29.3K
- AMRN 50.5K
- Earning Date
- EMF 01-01-0001
- AMRN 10-29-2025
- Dividend Yield
- EMF 6.16%
- AMRN N/A
- EPS Growth
- EMF N/A
- AMRN N/A
- EPS
- EMF N/A
- AMRN N/A
- Revenue
- EMF N/A
- AMRN $219,361,000.00
- Revenue This Year
- EMF N/A
- AMRN N/A
- Revenue Next Year
- EMF N/A
- AMRN N/A
- P/E Ratio
- EMF N/A
- AMRN N/A
- Revenue Growth
- EMF N/A
- AMRN N/A
- 52 Week Low
- EMF $10.58
- AMRN $7.08
- 52 Week High
- EMF $12.67
- AMRN $17.49
- Technical
- Relative Strength Index (RSI)
- EMF 79.28
- AMRN 51.27
- Support Level
- EMF $15.08
- AMRN N/A
- Resistance Level
- EMF $16.10
- AMRN $15.46
- Average True Range (ATR)
- EMF 0.28
- AMRN 0.45
- MACD
- EMF 0.10
- AMRN -0.59
- Stochastic Oscillator
- EMF 93.14
- AMRN 94.61
About EMF Templeton Emerging Markets Fund
Templeton Emerging Markets Fund is a closed-end management investment company. It seeks long-term capital appreciation by investing, under normal market conditions, at least 80% of its net assets in emerging country equity securities. It invests in various sectors such as Pharmaceuticals, Beverages, Broadline Retail, Metals &Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, insurance, Entertainment, and others.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.